此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Assessment of 3D Angular Arm Velocity During Elevation in People With Subacromial Pain Syndrome Pre-post Rehabilitation: a Pilot Study (CoiFFaX)

2026年6月3日 更新者:Assistance Publique - Hôpitaux de Paris
Clinicians need accurate, simple and interpretable indicators to evaluate shoulder 3 performance, including movement speed. The primary objective was to assess the changes in mean 4 angular velocity norm and velocity variation measured by an innovative score, after rehabilitation. The 5 secondary objective was to assess the relationship between changes in both velocity variables and in 6 shoulder pain and activity limitation.

研究概览

详细说明

Current clinical assessment of shoulder pain focus on range of motion (RoM), clinical tests and disability, but lack information on shoulder performance. Shoulder performance is an imprecise multidimensional concept including RoM, accuracy, smoothness, and velocity. Clinicians need simple and accurate methods to measure shoulder performance.

Rotator cuff lesions are the most common shoulder pathologies. These pathologies include a wide range of soft-tissue conditions surrounding the humeral head that are grouped under the term subacromial pain syndrome (SPS). SPS is associated with pain, decreased active shoulder elevation, activity limitation and decreased quality of life. Physiotherapy is the first-line treatment for chronic SPS for pain and function.

Inertial measurement units (IMUs) have been used to assess velocity variables in people with SPS. The intra- and inter-observer reliability of kinematic temporal variables measured using IMUs is excellent in people with shoulder disorders. Most studies assessed functional arm activities rather than analytic arm elevation movements that are typically evaluated in clinical practice. Furthermore, they used rather complex kinematic temporal parameters (cumulative velocity distribution, power, moment or asymmetry scores) that can lack interpretability for clinicians. We wanted to employ accurate and clinically meaningful velocity variables used to assess arm movements during standard clinical shoulder examinations.

研究类型

观察性的

注册 (实际的)

13

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • IDF
      • Paris、IDF、法国、75014
        • Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Hôpital Cochin

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

Unilateral subacromial pain syndrome diagnosed by a physician using clinical tests and imaging, enrolled in a usual care 4-session rehabilitation program in the PMR outpatient department.

描述

Inclusion Criteria:

  1. Age ≥18 years,
  2. unilateral SPS diagnosed by a physician using clinical tests and imaging,
  3. enrolled in a usual care 4-session rehabilitation program in the PMR outpatient department.

Exclusion Criteria:

  1. shoulder fracture or dislocation or shoulder surgery (with implant) <1 year previously,
  2. SLAP lesion,
  3. neurological pathology,
  4. cervico-brachial neuralgia.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Subacromial pain syndrome
1
Assessment of 3D angular arm velocity during elevation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mean angular velocity norm in degrees per second
大体时间:Day 0
The angular velocity norm provides a measure of velocity during arm elevation, taking into account the 3 movement axes and not only the main movement axis.
Day 0
Mean angular velocity norm in degrees per second
大体时间:Day 21
The angular velocity norm provides a measure of velocity during arm elevation, taking into account the 3 movement axes and not only the main movement axis.
Day 21
Velocity variation during movement time
大体时间:Day 0
By normalizing the cumulative velocity change by the highest frame-to-frame variation, this metric captures the overall irregularity of motion.
Day 0
Velocity variation during movement time
大体时间:Day 21
By normalizing the cumulative velocity change by the highest frame-to-frame variation, this metric captures the overall irregularity of motion.
Day 21

次要结果测量

结果测量
措施说明
大体时间
Numeric Rating Scale
大体时间:Day 0
Pain intensity assessed on a Numeric Rating Scale (NRS, 0-100, 0: no pain, 100: maximum pain imaginable)
Day 0
Numeric Rating Scale
大体时间:Day 21
Pain intensity assessed on a Numeric Rating Scale (NRS, 0-100, 0: no pain, 100: maximum pain imaginable)
Day 21
Quick DASH Questionnaire
大体时间:Day 0
Measurement of disability and symptoms of musculoskeletal disorders related to upper limb impairment (DASH self-report questionnaire; 30 = no functional impairment to 150 = maximum impairment)
Day 0
Quick DASH Questionnaire
大体时间:Day 21
Measurement of disability and symptoms of musculoskeletal disorders related to upper limb impairment (DASH self-report questionnaire; 30 = no functional impairment to 150 = maximum impairment)
Day 21
SPADI self-administered questionnaire
大体时间:Day 0
Pain and disability (SPADI self-administered questionnaire), pain subscore (0: no pain, 50: maximum imaginable pain) and disability subscore (0: no disability, 80: maximum signs of disability).
Day 0
SPADI self-administered questionnaire
大体时间:Day 21
Pain and disability (SPADI self-administered questionnaire), pain subscore (0: no pain, 50: maximum imaginable pain) and disability subscore (0: no disability, 80: maximum signs of disability).
Day 21
FABQ self-administered questionnaire on shoulder pain
大体时间:Day 0
Misconceptions and apprehension regarding physical activities and work (FABQ-Shoulder self-report questionnaire), physical activities subscore (questions 2, 3, 4, 5: 0 = no apprehension/misconceptions, 24 = maximum signs of apprehension/misconceptions) and work subscore (questions 6, 7, 9, 10, 11, 12, 15: 0 = no apprehension/misconceptions, 42 = maximum signs of apprehension/misconceptions)
Day 0
FABQ self-administered questionnaire on shoulder pain
大体时间:Day 21
Misconceptions and apprehension regarding physical activities and work (FABQ-Shoulder self-report questionnaire), physical activities subscore (questions 2, 3, 4, 5: 0 = no apprehension/misconceptions, 24 = maximum signs of apprehension/misconceptions) and work subscore (questions 6, 7, 9, 10, 11, 12, 15: 0 = no apprehension/misconceptions, 42 = maximum signs of apprehension/misconceptions)
Day 21

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月1日

初级完成 (实际的)

2025年6月30日

研究完成 (实际的)

2025年7月30日

研究注册日期

首次提交

2026年6月3日

首先提交符合 QC 标准的

2026年6月3日

首次发布 (实际的)

2026年6月9日

研究记录更新

最后更新发布 (实际的)

2026年6月9日

上次提交的符合 QC 标准的更新

2026年6月3日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • APHP260761

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅